These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 10428909)

  • 1. In vitro and in vivo activities of Syn2190, a novel beta-lactamase inhibitor.
    Nishida K; Kunugita C; Uji T; Higashitani F; Hyodo A; Unemi N; Maiti SN; Phillips OA; Spevak P; Atchison KP; Salama SM; Atwal H; Micetich RG
    Antimicrob Agents Chemother; 1999 Aug; 43(8):1895-900. PubMed ID: 10428909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. beta-Lactamase expression and outer membrane protein changes in cefpirome-resistant and ceftazidime-resistant gram-negative bacteria.
    Piddock LJ; Traynor EA
    J Antimicrob Chemother; 1991 Aug; 28(2):209-19. PubMed ID: 1778852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of tazobactam on the frequency of the emergence of resistant strains from Enterobacter cloacae, Citrobacter freundii, and Proteus vulgaris (beta-lactamase derepressed mutants).
    Higashitani F; Nishida K; Hyodo A; Inoue M
    J Antibiot (Tokyo); 1995 Sep; 48(9):1027-33. PubMed ID: 7592048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of conalbumin on the activity of Syn 2190, a 1,5 dihydroxy-4-pyridon monobactam inhibitor of AmpC beta-lactamases.
    Babini GS; Livermore DM
    J Antimicrob Chemother; 2000 Jan; 45(1):105-9. PubMed ID: 10629020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potentiation of beta-lactams against Pseudomonas aeruginosa strains by Ro 48-1256, a bridged monobactam inhibitor of AmpC beta-lactamases.
    Livermore DM; Chen HY
    J Antimicrob Chemother; 1997 Sep; 40(3):335-43. PubMed ID: 9338484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The in vitro activity and beta-lactamase stability of cefpirome (HR 810), a pyridine cephalosporin agent active against staphylococci, Enterobacteriaceae and Pseudomonas aeruginosa.
    Neu HC; Chin NX; Labthavikul P
    Infection; 1985; 13(3):146-55. PubMed ID: 3928497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12).
    Sader HS; Farrell DJ; Castanheira M; Flamm RK; Jones RN
    J Antimicrob Chemother; 2014 Oct; 69(10):2713-22. PubMed ID: 24917579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity of cefpirome against beta-lactamase-inducible and stably derepressed Enterobacteriaceae.
    Binfiglio G; Stefani S; Nicoletti G
    Chemotherapy; 1994; 40(5):311-6. PubMed ID: 7956454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of cefpirome (HR810) against Pseudomonas aeruginosa strains with characterised resistance mechanisms to beta-lactam antibiotics.
    Gargalianos P; Oppenheim BA; Skepastianos P; Livermore DM; Williams RJ
    J Antimicrob Chemother; 1988 Dec; 22(6):841-8. PubMed ID: 3149631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro antibacterial activity of FK037, a novel parenteral broad-spectrum cephalosporin.
    Mine Y; Watanabe Y; Sakamoto H; Hatano K; Kuno K; Higashi Y; Kamimura T; Matsumoto Y; Tawara S; Matsumoto F
    J Antibiot (Tokyo); 1993 Jan; 46(1):71-87. PubMed ID: 8436562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chequerboard titration of cephalosporin CXA-101 (FR264205) and tazobactam versus beta-lactamase-producing Enterobacteriaceae.
    Livermore DM; Mushtaq S; Ge Y
    J Antimicrob Chemother; 2010 Sep; 65(9):1972-4. PubMed ID: 20595207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
    Vidaillac C; Leonard SN; Sader HS; Jones RN; Rybak MJ
    Antimicrob Agents Chemother; 2009 Jun; 53(6):2360-6. PubMed ID: 19349512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanism of suppression of piperacillin resistance in enterobacteria by tazobactam.
    Kadima TA; Weiner JH
    Antimicrob Agents Chemother; 1997 Oct; 41(10):2177-83. PubMed ID: 9333044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro antibacterial activities of FK037: a new parenteral cephalosporin.
    Inoue K; Inoue E; Mitsuhashi S
    Chemotherapy; 1995; 41(4):257-66. PubMed ID: 7555206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deciphering the Evolution of Cephalosporin Resistance to Ceftolozane-Tazobactam in Pseudomonas aeruginosa.
    Barnes MD; Taracila MA; Rutter JD; Bethel CR; Galdadas I; Hujer AM; Caselli E; Prati F; Dekker JP; Papp-Wallace KM; Haider S; Bonomo RA
    mBio; 2018 Dec; 9(6):. PubMed ID: 30538183
    [No Abstract]   [Full Text] [Related]  

  • 16. Cefpirome Treatment Results in Limited Selection of Stable Derepressed
    Gautam V; Mouton JW; Ten Kate MT; Bakker-Woudenberg IAJM; van Burgh S; Strepis N; Klaassen CHW; Goessens W
    Microb Drug Resist; 2020 Apr; 26(4):341-348. PubMed ID: 31657651
    [No Abstract]   [Full Text] [Related]  

  • 17. Multicentre comparative study on the antibacterial activity of FK-037, a new parenteral cephalosporin.
    Martínez-Beltrán J; Cantón R; Liñares J; García de Lomas J; Gimeno C; Tubau F; Baquero F
    Eur J Clin Microbiol Infect Dis; 1995 Mar; 14(3):244-52. PubMed ID: 7614970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamics of Ceftolozane plus Tazobactam Studied in an In Vitro Pharmacokinetic Model of Infection.
    MacGowan AP; Noel AR; Tomaselli SG; Nicholls D; Bowker KE
    Antimicrob Agents Chemother; 2016 Jan; 60(1):515-21. PubMed ID: 26552975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ceftazidime, a pseudomonas-active cephalosporin: in-vitro antimicrobial activity evaluation including recommendations for disc diffusion susceptibility tests.
    Jones RN; Barry AL; Thornsberry C; Gerlach EH; Fuchs PC; Gavan TL; Sommers HM
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():187-211. PubMed ID: 19802985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro antimicrobial activity of cefpirome against ceftazidime-resistant isolates from two multicenter studies.
    Sader HS; Jones RN
    Eur J Clin Microbiol Infect Dis; 1994 Aug; 13(8):675-9. PubMed ID: 7813503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.